Fujifilm accelerates the production of antiviral drug “Avigan Tablet” for COVID-19

Gary Pageau ,

Register to get 3 free articles

Support the Dead Pixels Society and get access to exclusive content by becoming a subscriber!

No spam Unsubscribe anytime

Want unlimited access? View Plans

Already have an account? Sign in

FUJIFILM Corp. announced the expansion of its manufacturing capacity at FUJIFILM Toyama Chemical Co. Ltd. to significantly increase the production of its influenza antiviral drug “Avigan Tablet” for treating patients with COVID-19. To further boost the supply of Avigan, Fujifilm is also allocating additional capacity at its FUJIFILM Wako Pure Chemical Co. Ltd. facility in Japan, for the production of pharmaceutical intermediates used to manufacture Avigan. In addition, Fujifilm has established strategic partnerships with domestic and overseas companies for various manufacturing processes to source raw materials and pharmaceutical substances.

Fujifilm expects to progressively increase the monthly production of Avigan up to 100,000 treatment courses by July 2020, approximately 2.5 times more compared to the beginning of March, when the company first began its current production run. In addition, Fujifilm plans to further accelerate production up to 300,000 treatment courses by September 2020.

Written by 

Gary Pageau is principal of InfoCircle LLC, continuing his marketing communications career. InfoCircle LLC is a marketing and communications consulting firm, specializing in business-to-business markets. For nearly 25 years, he was with PMA International, serving most recently as Publisher, Content Development and Strategic Initiatives. His primary responsibilities included overseeing the Association’s editorial department, marketing research unit, education and corporate relations department.